Analysts meticulously research for up to 3-4 months to put together one suite of reports, a MedSuite, which is a comprehensive analysis of a group of healthcare markets. This MedCore is one portion of that analysis which focuses on the Liquid Embolics market segment and provides detailed analysis on the Market Size, Unit Sales, ASPs, and Company Market Shares.
Liquid Embolics Market Insights
In 2019, growth in the U.S. liquid embolics market continued to slow down. In 2006, “A Randomized Trial of Unruptured Brain Arteriovenous Malformations” (ARUBA) compared interventional and conservative treatment of arteriovenous malformations in the brain and found that conservative management with medication was more effective than embolization. Several issues with the device began to surface in the following decade. Thus, the market is expected to continue climbing in the low single-digits, due to a slowdown in unit sales.
Liquid Embolics Market Insights
In 2019, growth in the U.S. liquid embolics market continued to slow down. In 2006, “A Randomized Trial of Unruptured Brain Arteriovenous Malformations” (ARUBA) compared interventional and conservative treatment of arteriovenous malformations in the brain and found that conservative management with medication was more effective than embolization. Several issues with the device began to surface in the following decade. Thus, the market is expected to continue climbing in the low single-digits, due to a slowdown in unit sales.
